The Biotechnology Industry Organization (BIO, Washington, DC) named James C. Mullen, president and CEO of Biogen Idec Inc., chairman of the Biotechnology Industry Organization. In addition to Mullen, five BIO board members have been named officers for 20052006, along with 11 new BIO members.
The following BIO board members have been named officers for 2005–2006:
–Vice Chair, Healthcare: Joshua Boger, Ph.D., Chairman, President and CEO, Vertex Pharmaceuticals, Inc.
–Vice Chair, Food and Agriculture: W. Pete Siggelko, Vice President, Plant Genetics & Biotechnology, Dow AgroSciences, LLC
–Secretary: Joseph C. Scodari, Company Group Chairman, Biopharmaceuticals, Johnson & Johnson
–Treasurer: Stephen A. Sherwin, M.D., Chairman and CEO, Cell Genesys, Inc.
BIO membership also has elected 11 new members to the organization's Boardof Directors:
–Catherine M. Bonuccelli, M.D., Vice President, External Scientific Affairs, AstraZeneca Inc.
–Geoffrey F. Cox, Ph.D., Chairman, President and CEO, GTC Biotherapeutics Inc.
–Rachel K. King, CEO, GlycoMimetics Inc.
–John M. Leonard, M.D., Vice President, Global Medical & Scientific Affairs, Abbott Laboratories Inc.
–Gregory T. Lucier, Chairman and CEO, Invitrogen Corporation
–Thomas H. McLain, Chairman, President and CEO, Nabi Biopharmaceuticals
– Thomas B. Okarma, M.D., Ph.D., President, CEO and Director, Geron Corporation
–David E. I. Pyott, Chairman, President and CEO, Allergan Inc.
–Feike Sijbesma, M.B.A., Managing Board of Directors, DSM NV
–Martin Soerters, President, U.S., Novo Nordisk Inc.
–Peter F. Young, President and CEO, AlphaVax Inc.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.